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Pure tone audiometry (PTA);
Sensorineural hearing loss
(SNHL);
SLE disease activity index
(SLEDAI)Abstract Aim of the work: To evaluate the hearing disorders in SLE patients with particular
regard to their frequency and relationship to disease duration and activity.
Patients and methods: Twenty female SLE patients were enrolled in the study. Assessment of dis-
ease activity was done using the SLE disease activity index (SLEDAI). Another 20 otologically
healthy subjects of matched age and sex served as controls. Auditory assessment was performed
and included otoscopic examination, pure tone audiometry (PTA), acoustic immittance testing
and speech audiometry.
Results: The PTA was abnormal in 13 (65%) patients; 4 had tinnitus and 1 vertigo. The PTA
results showed a highly signiﬁcant statistical difference from the control (p< 0.001). Otoscopic
examination, acoustic immittance testing and speech audiometry of all patients were normal. A sig-
niﬁcant difference was found in the age at disease onset between those with and without abnormal
PTA (p= 0.023). Moreover, there was a signiﬁcantly lower hearing level (right ear) at 12,000 Hz in
juvenile-onset (N= 6) (20.83 ± 3.76 db) compared to adult-onset cases (32.5 ± 15.66 db)
(p= 0.02). No signiﬁcant difference was present in the audiovestibular manifestations
(p= 0.114), clinical, laboratory parameters or disease activity between those with or without hear-
ing loss. However, hearing levels were signiﬁcantly lower in those with lupus nephritis and those
receiving hydroxychloroquine.
118 A.N. Mokbel et al.Conclusion: Pure tone audiometry revealed SNHL in 65% of SLE patients. Absence of audio-
vestibular manifestations does not exclude inner ear affection. Age at disease onset is remarkably
associated with hearing loss in SLE. Lupus nephritis and hydroxychloroquine use are associated
with lower hearing levels and possible early hearing loss.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis.Open access under CC BY-NC-ND license.1. Introduction
Systemic lupus erythematosus (SLE) is associated with
several comorbidities, including hearing and vestibular disor-
ders [1]. Sensorineural hearing loss (SNHL) is remarkably pres-
ent in SLE [2]. Different mechanisms leading to SNHL in SLE
patients and in those with antiphospholipid syndrome (APS)
have been proposed, such as secondary vasculitis, microinfarc-
tions of the capillaries or arterioles in the temporal bone and
thrombosis in the otologic region [3]. Hearing loss in SLE may
be potentially due to autoimmunity, vasculitis, premature pres-
byacousis and drug ototoxicity [4]. Gazquez et al. [5] showed
autoimmunity to be associated with the pathophysiology of
Meniere’s disease (MD), an inner ear disorder characterized
by episodes of vertigowith hearing loss and tinnitus. They found
an elevated prevalence of systemic autoimmune disease such as
SLE with MD. This ﬁnding suggested an autoimmune back-
ground in the pathophysiology of hearing loss. In the mouse
model of SLE, immunoglobulin G deposits on the thickened
basement membranes of capillaries in the stria vascularis and
ultimately signiﬁcant hearing loss (HL) have been reported [6].
In an SLE patient with serous effusion and hemorrhage in
both middle ears, the right cochlea, vestibule, semicircular ca-
nals and vestibular aqueduct were ﬁlled with dense ﬁbrous tis-
sue and new bone formation. The histopathologic examination
revealed a dense perivascular accumulation and inﬁltration of
inﬂammatory cells and vasculitis in the ﬁbrous tissue [7].
Localization of hearing loss in SLE is known as a cochlear
lesion but other sites may be also involved. In the work of
Maciaszczyk and his colleagues [8], an increase of neural con-
duction was observed in SLE patients compared to controls,
which suggested subclinical retrocochlear or central involve-
ment of the auditory pathway.
In the study byMaciaszczyk et al. [8] it was found that SLE
patients had poorer hearing thresholds than the age-matched
controls. Furthermore, Roverano et al. [9] showed that 66%
of SLE patients revealed an asymptomatic SNHL at high
frequencies with statistically signiﬁcant differences when com-
pared with the control group. Sudden SNHL may be a mani-
festation of SLE and may have an important impact on the
health of these patients [10].
The aim of this study is to evaluate the hearing disorders in
patients with SLE with particular regard to their frequency
and relationship to disease duration and activity.2. Patients and methods
Twenty female patients with SLE fulﬁlling the updated Amer-
ican College of Rheumatology (ACR) revised classiﬁcation
criteria for the SLE [11] were enrolled into the study. Assess-
ment of disease activity was done using the SLE disease
activity index (SLEDAI) [12]. The control group consisted of20 otologically healthy persons matched to the SLE group
for age and sex. The patients were selected from the outpatient
clinic and inpatient section of Rheumatology and Rehabilita-
tion department, Faculty of Medicine, Cairo University Kasr
el Ainy Hospital. An informed consent was obtained from
all participants in the study, and the study was approved by
the Institutional Review Board (IRB) of faculty of medicine,
Cairo University.
Patients or control with any of the following were excluded
from the study: Diabetes, uncontrolled hypertension for more
than one year duration, history of ototoxicity due to drugs e.g.
Aminoglycosides, history of noise exposure e.g. occupational
as working in a factory, history of fever which causes affection
of hearing e.g. Measles, Mumps, Rubella & Meningitis, his-
tory of neurological disease that causes affection of hearing
e.g. multiple sclerosis (MS) and a family history of hearing
loss.
All patients included in this study were subjected to:
1- Comprehensive history taking including auditory symp-
toms such as hearing loss, tinnitus, vertigo, earache and
thorough general and clinical examination of the cardio-
pulmonary, abdominal, neurological and musculoskele-
tal systems.
2- Routine laboratory investigations including complete
blood count (CBC), erythrocyte ‘/isedimentation rate
(ESR), liver and kidney functions, and urine analysis,
in addition to estimation of total albumin in 24 h urine,
immunological assays (anti-nuclear antibody; ANA,
anti-double stranded deoxyribonucleic acid antibodies;
anti-dsDNA, anti-cardiolipin antibodies, and lupus
anticoagulants), and serum complement levels (C3 and
C4).
3- Auditory assessment was done by an audiologist and
included the following: otoscopic examination [13], pure
tone audiometry (PTA) [14], acoustic immittance testing
(tympanometry and acoustic reﬂex) [15] and speech
audiometry [16].
Statistical analysis: Data were statistically described in
terms of mean ± standard deviation (SD), median and range,
or frequencies (number of cases) and percentages when appro-
priate. Comparison of numerical variables between the study
groups was done using Student t test for independent samples
when variables were normally distributed and Mann–Whitney
U test for independent samples when not normally distributed.
For comparing categorical data, Chi square (v2) test was
performed. Exact test was used instead when the expected
frequency is less than 5. p values less than 0.05 was considered
statistically signiﬁcant. All statistical calculations were done
using computer programs SPSS (Statistical Package for the
Social Science; SPSS Inc., Chicago, IL, USA) version 15 for
Microsoft Windows.
Table 2 Laboratory features of systemic lupus erythematosus
(SLE) patients.
Laboratory data Range mean ± SD
ESR(mm/ 1st h) 10–130 69.05 ± 40.49
ALT(U/L) 7–44 18.4 ± 10.71
AST(U/L) 9–129 26.85 ± 26.32
Creatinine(mg/dl) 0.4–3.5 0.79 ± 0.65
Urea (mg/dl) 5–201 35.4 ± 41.19
Urinary protein (gm/24 h) 0.0–3.4 0.58 ± 0.93
Immune proﬁle No. %
Positive ANA 20 100
Positive anti-DNA 20 100
swPositive ACL IgM 3 15
Positive ACL IgG 1 5
Positive LAC 2 10
Consumed C3 and C4 2 10
ESR: erythrocyte sedimentation rate, ALT: alanine transaminase,
AST: aspartate transaminase, ANA: anti-nuclear antibodies, DNA:
deoxynucleic acid, ACL: anticardiolipin, LAC: lupus anticoagu-
lant, C: complement.
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This study included 20 female SLE patients. Their age ranged
from 20 to 48 years, with mean age of 28.8 ± 9.36 years. Their
age of onset of SLE ranged from 14 to 41 years, with mean age
of onset 24.6 ± 9.01 years. Six patients had disease onset be-
fore 18. The disease duration ranged from 2 months to 9 years,
with mean duration 47.85 ± 34.15 months. The control group
included 20 age and sex matched otologically healthy individ-
uals. Their ages ranged from 22 to 49 years, with mean age of
33 ± 8.03 years. There was no statistically signiﬁcant differ-
ence in the median age between the patient and the control
groups. The clinical characteristics of the SLE patients are pre-
sented in Table 1 and the laboratory features in Table 2.
3.1. Audiovestibular symptoms of SLE patients
4 (20%) patients had tinnitus and 1 (5%) patient had vertigo.
15 (75%) patients had no audiovestibular symptoms. None of
the patients complained of earache, ear fullness or hearing loss.
None of the patients gave history of ear infection, occupa-
tional exposure to noise or family history of hearing loss.
3.2. Disease activity assessment
The SLEDAI score ranged from 4 to 29 with a mean of
14.8 ± 6.5.Table 1 Clinical characteristics of the systemic lupus erythe-
matosus (SLE) patients.




Weight loss 8 40
Fatigue 13 65
Mucocutaneous manifestations
Malar rash 18 90
Oral ulcers 16 80
Maculopapular rash 6 30










Cranial nerve neuropathy 1 5
Peripheral neuropathy 1 5
Lupus headache 4 20
Cognitive dysfunction 1 5
Pleurisy/pleural eﬀusion 4 20
Pericarditis/pericardial eﬀusion 2 10
Raynaud’s phenomenon 4 20
Nephritis 7 35
Autoimmune hepatitis 1 5
Antiphosholipid syndrome 0 03.3. Medications of the SLE patients
10 (50%) patients were on corticosteroids only and another 10
(50%) were on a combination therapy of corticosteroids, aza-
thioprine and hydroxychloroquine. All patients received ste-
roids in a daily dose ranging from 5 to 45 mg with mean of
19 ± 10.46, hydroxychloroquine daily dose ranged from 200
to 400 mg with mean of 340 ± 96.6 and azathioprine daily
dose ranged from 50 to 150 mg with mean of 85 ± 24.15.
3.4. Results of auditory assessment
Pure tone audiometry (PTA) was abnormal in 13 (65%) pa-
tients and normal in 7 (35%) patients. Results of otoscopic
examination, acoustic immitance testing and speech audiome-
try of all patients (100%) were normal. All patients had
96–100% speech discrimination scores and type A tympano-
gram. The acoustic reﬂex showed thresholds consistent with
the level of hearing loss.
Pure tone audiometry revealed hearing loss in 13 (65%) of
SLE patients, while all controls (100%) showed normal hear-
ing. None of the controls had any hearing loss as their PTA
revealed bilaterally normal thresholds, their speech discrimina-
tion scores reached 96–100% and the tympanogram did not
show any abnormality. There was a highly signiﬁcant statisti-
cal difference between SLE patients and the control group as
regards PTA (p< 0.001).
Of the thirteen SLE patients who had abnormal pure-tone
thresholds, 2 (10%) patients had bilateral symmetrical hearing
loss, 8 (40%) patients had bilateral asymmetrical hearing loss,
and 3 (15%) patients had unilateral hearing loss.
Two patients had low tone loss and 11 patients had high
tone loss. The mean values of the air-conduction hearing
thresholds in SLE patients were poorer than in control group
for frequencies 250, 8000 and 12,000 Hz (Fig. 1).
The hearing level of the right ear at a frequency of
12,000 Hz was signiﬁcantly lower in the 6 SLE patients with
juvenile onset of the disease (20.83 ± 3.76 db) compared to
Table 3 Relation between audiovestibular manifestations and
hearing loss as determined by pure tone audiometry (PTA).








120 A.N. Mokbel et al.the 14 adult onset cases (32.5 ± 15.66 db) (p= 0.02). There
was no signiﬁcant difference at other frequencies however
there was a tendency to decrease in the left ear (at
12,000 Hz) in the juvenile onset cases (28.33 ± 8.16 db vs.
42.86 ± 22.93 db; p= 0.052).
3.5. Relation between audiovestibular symptoms and hearing loss
The 5 patients with auditory manifestations all had hearing
loss as determined by PTA. The other 8 patients with abnor-
mal PTA results had no auditory manifestations. The patient
with vertigo was one of 2 (15.3%) patients that proved by
PTA to have mild low tone loss, while the rest of the patients
had high tone loss. There was no signiﬁcant difference in the
audiovestibular manifestations according to the PTA results
(p= 0.114). Table 3 shows the relation between audiovestibu-
lar manifestations and hearing loss.
3.6. Relation between demographic, clinical and laboratory
features as well as medications used and hearing level
Comparison of the demographic features, clinical and labora-
tory characteristics as well as the medications received by the
SLE patients according to the hearing state as determined by
the pure tone audiometry (PTA) is presented in Table 4.
On comparing the hearing level according to the presence
or absence of clinical manifestations, only lupus nephritis
showed a signiﬁcant difference at various PTA frequencies
(Table 5).
On comparing the hearing level according to intake of med-
ications, it was signiﬁcantly lower in those receiving azathio-
prine and hydroxychloroquine (N= 10) in the right
(12 ± 4.83 db) and left (13 ± 6.75 db) ears compared to those
not receiving (N= 10) (19.5 ± 6.85 db and 20 ± 7.07 db;
p= 0.012 and p= .036 respectively) at a frequency of 4000 Hz.
4. Discussion
Hearing loss in systemic lupus erythematosus may be
potentially due to autoimmunity, vasculitis, premature pres-




















Figure 1 Mean pure tone audiogram of SLE paThis study, which was performed in Kasr al Aini University
Hospitals, included 20 female SLE patients. The 20 SLE pa-
tients were subjected to auditory assessment using PTA, tym-
panometry, acoustic reﬂexes and speech audiometry. All
other tests except PTA were normal. All patients had
96–100% speech discrimination scores and type A tympano-
gram. Also acoustic reﬂex showed thresholds consistent with
the level of hearing loss.
None of the healthy controls had any kind of hearing loss,
their PTA revealed bilaterally normal thresholds, their speech
discrimination scores reached 96–100% and the tympanogram
did not show any abnormality. As regard PTA in SLE
patients, 13 (65%) had abnormal pure tone threshold while 7
(35%) had normal hearing threshold. These results are in
accordance with the ﬁndings of Roverano et al. [9] that showed
20/30 (66%) SLE patients to have SNHL at high frequencies
with statistically signiﬁcant differences when compared with
the control. Other studies showed different results, as in the
work of Bowman and colleagues, hearing loss was observed
in only 2/30 (8%) of the SLE patients and Kastanioudakis
et al. reported hearing loss in 22.5% (8/43) female SLE
patients [17,18]. In the study of Maciaszczyk et al. [8] they
found that SLE patients had poorer hearing thresholds than
the age-matched controls and SNHL was observed in 28.6%.
Inspite of different results regarding the auditory affection
in SLE patients, auditory system involvement ought to be con-
sidered as one of elements of the clinical picture of SLE and an




tients (40 ears) compared to control (40 ears).
Table 5 Hearing level according to the presence or absence of lupus nephritis in the right and left ear.
Hearing level (db) mean ± SD (HZ) SLE patients
(N= 20)
p value
LN (N= 7) Without LN (N= 13)
Right ear 250 16.43 ± 3.78 23.85 ± 5.06 0.002
500 15 ± 4.08 20.77 ± 5.34 0.016
1000 13.57 ± 3.78 16.92 ± 4.8 0.11
2000 12.86 ± 2.67 13.46 ± 4.27 0.7
4000 12.86 ± 3.93 17.31 ± 7.8 0.11
8000 16.43 ± 4.76 25 ± 12.42 0.041
12,000 23.57 ± 9.45 31.92 ± 15.75 0.16
Left ear 250 14.29 ± 3.45 23.08 ± 5.6 0.000
500 12.86 ± 3.93 22.31 ± 5.63 0.000
1000 10.71 ± 1.89 18.46 ± 4.27 0.000
2000 10.71 ± 3.45 18.46 ± 6.58 0.003
4000 10 ± 0.00 20.0 ± 7.36 0.000
8000 17.14 ± 6.99 26.15 ± 12.44 0.053
12,000 32.14 ± 16.29 41.92 ± 22.41 0.28
SLE: Systemic lupus erythematosus, LN: lupus nephritis. Bold values are signiﬁcant at p< 0.05.
Table 4 Comparison of the demographic features, clinical and laboratory characteristics as well as medications received by the SLE
patients according to the hearing state as determined by pure tone audiometry (PTA).
Feature Hearing state in SLE patients p Value
Normal (n= 7) Hearing loss (n= 13)
Demographic features
Age (years) 24.43 ± 6.6 31.15 ± 9.99 0.621
Age of onset (years) 19.14 ± 5.24 27.54 ± 9.39 0.023*
Disease duration (months) 63.86 ± 38.84 39.23 ± 30.04 0.175
Clinical characteristics
Vasculitis 1 6 0.329
Cranial neuropathy 0 1 1
Peripheral neuropathy 0 1 1
Cognitive dysfunction 0 1 1
Lupus headache 2 2 0.61
Nephritis 4 3 0.24
SLEDAI (mean ± SD) 14.57 ± 7.52 14.92 ± 6.22 0.92
Laboratory features
ESR(mean ± SD) 70 ± 46.64 68.54 ± 38.83 0.812
ACL IgM positivity 1 2 0.476
ACL IgG positivity 1 0 0.606
LAC positivity 0 2 0.428
Medications used
Steroids only 4 6 1
Steroids, HCQ and AZA 3 7 1
* ESR: erythrocyte sedimentation rate, ACL: anticardiolipin, LAC: lupus anticoagulant. HCQ: hydroxychloroquine, AZA: azathioprine.
Demographic features, ESR and systemic lupus erythematosus disease activity index (SLEDAI) are presented as mean ± SD while the other
characteristics are presented as number of patients.
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apparatus and SNHL can affect a signiﬁcant proportion of
patients [19].
None of the patients with abnormal PTA results gave
symptoms of hypoacousis and this was in accordance with
another study on 40 female SLE patients, all of them
asymptomatic in terms of hearing impairment that found that
57.5% presented a subclinical sensorineural hearing abnormal-
ity [20]. The study of Roverano et al. [9] also revealed asymp-
tomatic SNHL in 66% of SLE patients. Karatas et al. [2]stated that PTA showed SNHL in 6/28 (21.4%) SLE
patients, yet symptomatic hearing loss was reported in 2
(7%). Moreover, the work of Gad et al. [21] showed that in
juvenile SLE, 25% of the SLE children had asymptomatic
SNHL.
Only 5 patients reported audiovestibular symptoms includ-
ing tinnitus in 4 (20%) and vertigo in 1 (5%). The patient with
vertigo was one of 2 (15.3%) patients that proved by PTA to
have mild low tone loss, while the rest of the patients had
high tone loss. There was no signiﬁcant difference in the
122 A.N. Mokbel et al.audiovestibular manifestations between those with normal
hearing or hearing loss.
In the work of Batuecas-Caletrio et al. [1] SNHL was found
to be associated with a history of episodic vertigo, but not at
time of assessment. Gomides et al. [19] observed in their study
that 25 (55.5%) SLE patients presented one or more symptoms
at the time of assessment, including vertigo, hypoacusis, ear
fullness or tinnitus. Analysis of audiometric alterations showed
SNHL in 7 (15.6%). The association between audiovestibular
symptoms and hearing loss in SLE patients needs further
investigations [19]. Vertigo and dizziness are not common
symptoms in SLE, but are probably present more often than
was formerly thought [22]. The prevalence of vertigo and/or
balance disorders reported by SLE patients varies between
13% and 67% [4].
Low tone hearing loss together with the presence of vertigo
detected in one of our SLE patients could be attributed to the
presence of hydrops. This showed agreement with Andonopoulus
et al. [20] who reported low frequency hearing loss and sup-
ported the possibility of the presence of subclinical hydrops in
SLE patients. In contrast Karatas et al. [2] reported vertigo in
8 (28%) SLE patients who had signiﬁcantly more peripheral
type vestibular pathology compared with the control. Prevalence
of vertigo in SLE was higher in patients with abnormal electro-
nystagmography (ENG) results. Abnormal ENG ﬁndings and
vestibular symptoms are probably present more often than were
formerly thought in SLE patients [2].
Gomides et al. [19] observed a marked prevalence of vertigo
(31.1%) in SLE patients and Maciaszczyk et al. [8] stated that
over 70% of SLE patients reported vertigo and dizziness in a
questionnaire. The association between audiovestibular symp-
toms and hearing loss in SLE patients needs further
investigations.
The mean values of the air-conduction hearing thresholds
in SLE patients were poorer than in control group for frequen-
cies 250, 8000 and 12,000 Hz. The results showed highly signif-
icant statistical difference between SLE patients and control as
regards PTA. 2 (10%) patients had bilateral symmetrical hear-
ing loss, 8 (40%) had bilateral asymmetrical hearing loss, while
3 (15%) had unilateral hearing loss. 2 (15.3%) had low tone
loss and 11 (84.6%) patients had high tone loss.
Most of the patients are typical of autoimmune hearing loss
as it is often regarded as bilateral, but asymmetrical. High-fre-
quency hearing loss is often attributed to tonotopic base to
apex differences in cochlea like viability of outer hair cells, vas-
cularization, and intrinsic susceptibility of basal hair cells to
free radicals, which make a basal turn receptor more sensitive
to damage.
Vasculitis processes, excessive generating of free radicals
and the cochlear pathology in the stria vascularis seem to dom-
inate in lupus pathology with hearing loss development in the
course of the disease [23].
This was in agreement with Kastanioudakis et al. [18] who
reported that out of 8 patients with hearing loss, 1 (12.5%)
had bilateral symmetric and 7 (87.5%) had bilateral asymmet-
ric hearing loss. Gomides et al. [19] stated that in most lupus
patients, the hearing loss was unilateral and classiﬁed as mild
or moderate. Karatas et al. [2] reported that out of 6 patients
with hearing loss, it was unilateral in 3 (50%) and bilateral
in 3 (50%). Batuecas-Caletrio et al. [1] stated that 19% of
the SLE patients showed hearing loss, mainly affecting higher
frequencies. In contrast, Maciaszczyk et al. [8] stated that inthe SLE patients, hearing loss was mainly bilateral, symmetri-
cal and affecting high frequencies. There were no cases of ﬂuc-
tuating hearing loss. This was frequently not typical of
autoimmune hearing loss as it is often regarded as bilateral,
but asymmetrical.
In the present study, there was no signiﬁcant statistical
association between disease duration and hearing loss. Previ-
ous researches yielded similar results. Andonopoulus et al.
[20] found no correlation between duration of SLE and the
presence of low frequency hearing loss which they attributed
to the presence of hydrops. Sperling et al. [4] concluded that
the disease duration did not have a signiﬁcant effect on the
results of their study. This also coincides with the ﬁndings of
Gomides et al. [19] reporting that there was no association
between SNHL and the duration of SLE. In opposition, a
signiﬁcant correlation between values of the mean air-conduc-
tion hearing thresholds and SLE duration was proved in the
work of Maciaszczyk et al. [8].
The present work showed a signiﬁcant statistical associa-
tion between age at disease onset and hearing loss in SLE pa-
tients with lower hearing levels at higher frequencies. This
relation was not previously reported in other studies and
should be considered in future longitudinal researches on a lar-
ger scale.
Of the twenty patients with SLE in this study 10 (50%),
were treated with corticosteroids only and 10 (50%) with a
combination of corticosteroids, hydroxychloroquine (HCQ)
and azathioprine. There was no signiﬁcant difference in the
medications received between those with and without hearing
loss. However, on comparing the hearing level according to in-
take of medications, there was a signiﬁcantly lower level in
those receiving azathioprine and hydroxychloroquine in the
right and left ears compared to those not receiving.
These results are in agreement with Kastanioudakis et al.
[18] who found that although most SLE patients were exposed
to potentially ototoxic medications (HCQ and frusemide), the
asymmetric results observed in 15/26 (58%) argue against oto-
toxicity as the cause of aural symptoms. At the time of the
study performed by Roverano et al. [8] 25/30 patients
(83.3%) were under treatment with HCQ (200 mg/day), and
16 exhibited SNHL. The remaining 5 patients, who had not
been treated with HCQ presented with SNHL. Wang and col-
leagues reported only one SLE patient out of 156 users re-
ceived 203 courses of antimalarials, to stop the medication
due to ototoxicity [24]. Besides the well-known retinal toxicity,
its use has been suspected of be associated to ototoxicity. Oto-
toxicity, SNHL, tinnitus, sense of imbalance and cochleoves-
tibular manifestations have been reported with use of
antimalarials. Alterations in hearing related to HCQ have been
reported; the reversibility of ototoxicity has been debatable,
but there is suggestion that such complication can be corrected
if the medication is stopped and appropriate therapy with
steroids is instituted [25].
In the present study, there was no association between
SNHL and clinical variables or laboratory parameters.
However, the hearing level was signiﬁcantly lower in those
with lupus nephritis which could be an early sign before the
development of hearing loss. No correlation was found
between the hearing level with renal or CNS involvement
and presence of antibodies [7]. Also, in the study of Gomides
et al. [19] no correlation was observed between hearing
loss and clinical manifestations or laboratory variables
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cas-Caletrio et al. [1] stated that in SLE patients, SNHL was
not associated with kidney disease, ANA or anti-phospholipid
positivity. In contrast, Sperling et al. [4] observed that aural
symptoms, like hearing loss and tinnitus, were more frequent
in SLE patients who had higher creatinine and lower C3 levels.
Although, the presence of antiphospholipid antibodies is a
proposed etiology for hearing loss in SLE patients [3], in this
study no statistical difference was found between the presence
of anti-phospholipid antibodies and hearing loss. Toubi et al.
[26] found that 27% of 30 patients with sudden SNHL were
positive for aCL compared to 0% in their control group. Naa-
rendrop and Spiera [27] also described six patients with SLE or
lupus-like syndrome who developed sudden SNHL with
elevated aPLs. Green and Miller [28] described a case of sud-
den SNHL in association with aPL as the ﬁrst manifestation
of SLE. In a recent study by Mouadeb et al. [29] in a cohort
of 168 patients with SNHL of unknown etiology, they found
42 patients (25%) with at least one elevated aPL antibody
and 20 patients had two or more positive aPL tests. An inter-
esting case of a 34-year-old pregnant woman with APS with
ﬂuctuating bilateral hearing loss was recently reported [30].
In another study, 5 (25%) patients had positive anti-
phospholipid antibodies and all of them had SNHL (100%),
4 (80%) had abnormal videonystagmography (VNG) results
and 3 (60%) had abnormal computerized dynamic posturogra-
phy (CDP) results [21]. Kastanioudakis et al. [18] did not ﬁnd
any correlation between the presences of anti-phospholipid
antibodies and hearing loss. In the work of Roverano et al.
[8] they stated that there was no statistically signiﬁcant relation
between antiphospholipid antibodies and SNHL.
In this work, no signiﬁcant statistical association between
disease activity using SLEDAI score and hearing loss could
be detected. This was in agreement with Gomides et al. [19]
as in their study no correlation was observed between hearing
loss in SLE patients and disease activity parameters. Further-
more, in the study of Gad et al. [21] there was no signiﬁcant
statistical correlation between SLEDAI scores and hearing loss
in SLE patients. Abbasi and colleagues [31] performed a case–
control study on 45 patients with SLE. The patients were
examined and evaluated for auditory and hearing problems
as well as parameters related to their disease severity and pro-
gression. No statistical signiﬁcant relationship was found be-
tween severity of the disease and hearing loss.
The results of this study should be interpreted in the context
of several limitations. First, the small number of the patients
was chosen. Second, the study did not exclude patients with
juvenile onset disease. Third, none of the patients included ful-
ﬁlled the criteria of diagnosis of APS which is a claimed cause
of auditory affection in SLE.
In conclusion, hearing affection is frequent in SLE patients
and since it is commonly asymptomatic, it could be neglected.
So regular screening of auditory functions of SLE patients
should be done, for better and early management. Age at dis-
ease onset is remarkably associated with hearing loss in SLE.
Lupus nephritis and hydroxychloroquine use are associated
with lower hearing levels and possible early hearing loss. Fur-
ther studies should work on how often this asymptomatic
SNHL progresses to a clinical problem to deﬁne the impor-
tance that SLE patients undergo audiometric tests as part of
their initial investigations.Conﬂict of interest
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